Received Feb 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
received hepatitis B dosing with Heplisav-B in April 2024 and June 2024 and the patient then received Twinrix in August 2024; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate schedule of vaccine administered in a adult female patient who received HAB (Twinrix) for prophylaxis. Concomitant products included Hepatitis b vaccine rHBsAg (yeast) (Heplisav b) and Hepatitis b vaccine rHBsAg (yeast) (Heplisav b). In AUG-2024, the patient received Twinrix. In AUG-2024, an unknown time after receiving Twinrix, the patient experienced inappropriate schedule of vaccine administered (Verbatim: received hepatitis B dosing with Heplisav-B in April 2024 and June 2024 and the patient then received Twinrix in August 2024). The outcome of the inappropriate schedule of vaccine administered was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 17-JAN-2025 The pharmacy intern reported that the patient that received hepatitis B dosing with Heplisav-B in April 2024 and June 2024 and the patient then received Twinrix, which led to Inappropriate schedule of vaccine administered. The reporter asked how to complete the hepatitis A series for this patient and at the time of call, no additional dosing had been administered. The Vaccine Administration Facility was the same as Primary Reporter
HEPLISAV B; HEPLISAV B